Clinical Trials

CNS

Glioblastoma

NCT04739670 2024-03-01

BELLA

31 enrolled

Recurrence, Triple Negative Breast Neoplasms

NCT05065021 2024-01-17

Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor

40 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06182800 2023-12-27

Adebrelimab Combined With Bevacizumab and Docetaxel for Advanced Non-Squamous Non-small Cell Lung Cancer After Progression on First-line Immunotherapy

35 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04395989 2023-12-22

FUTURE-SUPER

139 enrolled

Triple Negative Breast Neoplasms

NCT05833126 2023-12-15

Hepatic Arterial Infusion Chemotherapy in Combination With Atezolizumab and Bevacizumab for Second-line Treatment of Patients With Recurrent Liver Cancer After Liver Transplantation

25 enrolled

Recurrent Liver Cancer After Liver Transplantation

NCT04034459 2023-11-14

AIO-KRK-0116

109 enrolled

Colorectal Neoplasms

NCT04310176 2023-11-13

REVOLUTION

200 enrolled

Colorectal Neoplasms

NCT06060704 2023-10-11

Envafolimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of Refractory mCRC.

33 enrolled

Colorectal Neoplasms

NCT03818061 2023-09-28

ATHENA

33 enrolled

Head & Neck

Head and Neck Neoplasms

NCT06039202 2023-09-15

Phase 2 Study of CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Relapsed and/or Refractory Metastatic Colorectal Cancer

100 enrolled

Colorectal Neoplasms

NCT04262687 2023-08-18

POCHI

55 enrolled

Colorectal Cancer Metastatic

NCT04659382 2023-08-18

SIRTCI

52 enrolled

Colorectal Neoplasms

NCT03961698 2023-08-14

MARIO-3

91 enrolled

BreastGenitourinary

Breast Neoplasms, Carcinoma, Renal Cell, Triple Negative Breast Neoplasms

NCT03363867 2023-08-07

BEACON

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04724239 2023-08-01

Sintilimab and Chidamide in Combination With or Without IBI305 in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma

48 enrolled

Colorectal Neoplasms

NCT05965154 2023-07-28

Calizumab Combined With Bevacizumab and Capecitabine in the Treatment of Head and Neck Squamous Cell Carcinoma

22 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT05160896 2023-06-08

SALIRI Based Regimen as First-line Treatment for Advanced Metastatic Colorectal Cancer

90 enrolled

Advanced Metastatic Colorectal Cancer

NCT05886465 2023-06-02

HAIC Plus A+T for Patients With High-risk HCC: a Single-arm Phase 2 Trial

40 enrolled

Carcinoma, Hepatocellular

NCT05799820 2023-05-25

QL1706 Monotherapy or in Combination With Bevacizumab and XELOX as First-line Treatment of Unresectable Advanced or Metastatic CRC

60 enrolled

Colorectal Neoplasms

NCT05819060 2023-04-19

The Efficacy and Safety of The Fuzuloparib Combination With Bevacizumab

44 enrolled

Ovarian Neoplasms

NCT04974879 2023-03-29

Osimertinib Combined With Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions Metastatic Non-Small Cell Lung Cancer

20 enrolled

Bronchial Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT05267288 2023-03-29

Phase II Study of Afatinib Plus Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon G719X, S768I, and L861Q Mutation Metastatic Non-Small Cell Lung Cancer

PFS

NCT05616390 2023-03-21

Sintilimab Combined With Bevacizumab and Liver Protective Support Therapy in Unresectable Hepatocellular Carcinoma

Carcinoma, Hepatocellular

NCT03654833 2023-03-14

MiST

Other solid neoplasmThoracic

186 enrolled

Mesothelioma, Malignant

NCT05760599 2023-03-08

Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T

Carcinoma, Hepatocellular

NCT05163483 2023-03-06

Tucidinostat Plus PD-1 Inhibitor and Bevacizumab for Advanced Esophagus Cancer, AEG, Gastric Cancer

87 enrolled

Esophageal Squamous Cell Carcinoma

NCT05745857 2023-02-27

SLURP

25 enrolled

Adenocarcinoma Of Esophagus, Barrett Esophagus

NCT04872582 2023-02-23

Efficacy and Safety of Sintilimab Plus Bevacizumab in Metastatic Nasopharyngeal Carcinoma After Failure of Platinum-based Chemotherapy: An Open-label Phase II Study

33 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT05738317 2023-02-22

Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel in Non-squamous NSCLC After First-line Treatment

45 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04984980 2023-01-26

Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab in Unresectable Biliary Tract Cancer

37 enrolled

Biliary Tract Carcinoma

NCT05675033 2023-01-09

Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma

50 enrolled

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung

NCT05659290 2023-01-06

Alternating Treatment With Fruquintinib and Bevacizumab Plus Capecitabine as Maintenance Therapy After First-Line Treatment in Metastatic Colorectal Cancer

40 enrolled

Colorectal Neoplasms

NCT05611645 2022-11-10

Low-dose Bevacizumab With HSRT vs BVZ Alone for GBM at First Recurrence

42 enrolled

CNS

Glioma

NCT05588297 2022-10-20

Preoperative Nivolumab Plus Bevacizumab Combined With Chemotherapy Before Surgery in Patients With pMMR/MSS Colorectal Cancer Liver Metastases

12 enrolled

Colorectal Cancer Liver Metastases

NCT05325229 2022-10-13

A Study of Docetaxel for Injection (Albumin-bound) in Combination With Bevacizumab in Patients With Ovarian Cancer

94 enrolled

Platinum-resistant Recurrent Ovarian Cancer

NCT05314101 2022-08-23

TAS-102 Combined With Bevacizumab and Tislelizumab Third-line or Above in the Treatment of Liver Metastasis in Colorectal Cancer

25 enrolled

Colorectal Neoplasms

NCT04015739 2022-08-17

BOLD

74 enrolled

Carcinoma, Ovarian Epithelial, Recurrence

NCT01871571 2022-08-09

Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating Patients With Stage II-III Rectal Cancer

17 enrolled

Rectal Neoplasms

NCT04683965 2022-08-02

Pemetrexed and TAS-102 in Combination With Bevacizumab in Refractory Colorectal Cancer

27 enrolled

Colorectal Neoplasms

NCT04733963 2022-07-26

Fruquintinib Plus Capecitabine Versus Bevacizumab Plus Capecitabine as Maintenance Therapy Following First-line Treatment for Metastatic Colorectal Cancer

112 enrolled

Colorectal Neoplasms

NCT05247619 2022-07-15

A Clinical Study to Explore the Efficacy and Safety of Tislelizumab in Combination With Bevacizumab and Chemotherapy in Patients With Persistent, Recurrent, or Metastatic Cervical Cancer

49 enrolled

Uterine Cervical Neoplasms

NCT05444374 2022-07-05

A Phase II Study of Serplulimab Plus Bevacizumab in Combination With Chemotherapy in 1L Treatment of Untreated Recurrent or Metastatic Cervical Cancer

48 enrolled

Uterine Cervical Neoplasms

NCT05438108 2022-06-29

SBRT Sequential CapeOX Regimen Combined With Bevacizumab and Sintilimab in First-line Treatment of mCRC

Colorectal Neoplasms

NCT05303038 2022-06-09

Castle06(BC)

15 enrolled

Triple Negative Breast Neoplasms

NCT05398861 2022-06-01

Utidelone Combined With Bevacizumab in the Treatment of ≥ 2 Lines of HER-2 Negative Advanced Breast Cancer

71 enrolled

HER-2 Negative Breast Cancer

NCT05396937 2022-05-31

Efficacy and Safety of T+A+RAD in HCC

42 enrolled

Carcinoma, Hepatocellular

NCT05394233 2022-05-27

Tislelizumab +Bevacizumab+pc for Untreated EGFR+ and High PD-L1 Non-squamous NSCLC

20 enrolled

Non-squamous Non-small Cell Lung Cancer

NCT05158062 2022-04-26

Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer

35 enrolled

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT03126799 2022-04-06

AvaTa

128 enrolled